Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for a new medication, Amlodipine Besylate and Olmesartan Medoxomil Tablets, which is aimed at treating primary hypertension [1] Group 1 - The new drug is indicated for adult patients whose blood pressure control is inadequate with either Olmesartan Medoxomil or Amlodipine alone [1] - Each tablet contains 20mg of Olmesartan Medoxomil and 5mg of Amlodipine Besylate [1] - The approval of this drug enhances the company's product portfolio in the sartans category, which is expected to improve its market competitiveness in the cardiovascular disease treatment sector [1] Group 2 - The introduction of this medication is anticipated to have a positive impact on the company's future operating performance [1]

证券代码：002923 证券简称：润都股份 公告编号：2025-022 珠海润都制药股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形。 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开情况 珠海润都制药股份有限公司（以下简称"公司"）于2025年04月29日在公司指定 信息披露媒体《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资讯 网（www.cninfo.com.cn）上披露了《珠海润都制药股份有限公司关于召开2024年年 度股东大会的通知》（公告编号：2025-018），公司定于2025年05月20日以现场投票 与网络投票相结合的方式召开2024年年度股东大会。 中小股东出席的总体情况：通过现场和网络投票的中小股东137人，代表股份 1,044,327股，占公司有表决权股份总数的0.3118％。其中：通过现场投票的中小股 东2人，代表股份88,100股，占公司有表决权股份总数的0.0263％。通过网络投票的 中小股东135人，代表股 ...

广东广信君达律师事务所 广东广信君达律师事务所 关于珠海润都制药股份有限公司 关于珠海润都制药股份有限公司 2024 年年度股东会的 法律意见书 二〇二五年五月 地址：广东省广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 29 层、10 层、11 层（01-04 单元、10-11 单元） 邮编（P.C）：510623 电话（Tel）：020-37181333 传真（Fax）：020-37181388 网址（Website）：www.etrlawfirm.com 法律意见书 2024 年年度股东会的法律意见书 （（2025）粤广信君达律委字第 1378-2 号 致：珠海润都制药股份有限公司 广东广信君达律师事务所（（以下简称"本所"）接受珠海润都制药股份有限公 司（（以下简称"公司"）的委托，指派律师（（以下简称"本所律师"）出席公司 2024 年年度股东会（（以下简称"本次股东会"），并依据（ 中华人民共和国公司法》（以 下简称（ 公司法》）、（ 中华人民共和国证券法》（（以下简称（ 证券法》）（ 上 市公司股东会规则》和（ 珠海润都制药股份有限公司章程》（以下简称（ 公司章 程》）的有关规定对本次股 ...

Group 1 - The core viewpoint of the article highlights the decline of the artemisinin concept sector, which fell by 0.82%, ranking among the top declines in the concept sector [1][2] - Within the artemisinin concept sector, major companies such as Rundu Co., Zhejiang Medicine, and Kunming Pharmaceutical experienced significant declines, while only two stocks, Delong Huineng and Baiyunshan, saw increases of 1.06% and 0.37% respectively [1][2] - The article provides a detailed overview of the capital flow, indicating a net outflow of 58 million yuan from the artemisinin concept sector, with Rundu Co. leading the outflow at 43.43 million yuan [2] Group 2 - The article lists the top-performing concept sectors, with the military equipment restructuring concept leading with a gain of 3.92%, while the artemisinin concept was among the worst performers [2] - A table is provided showing the capital flow for various companies within the artemisinin concept, detailing their respective price changes and turnover rates, with Rundu Co. showing a significant outflow [2]

Group 1 - The company’s wholly-owned subsidiary, Run Du Pharmaceutical (Jingmen) Co., Ltd., has received the veterinary product approval number for "Florfenicol" from the Ministry of Agriculture and Rural Affairs [1][2] - The product is a commonly used veterinary antibiotic with a broad antibacterial spectrum, suitable for large-scale farming operations, primarily used for the prevention and treatment of bacterial diseases in cattle, poultry, pigs, and fish [1][2] - The approval number is valid from April 25, 2025, to April 24, 2030, indicating a significant timeline for market entry [1] Group 2 - The company has obtained the "Veterinary Production License" and "Veterinary GMP Certificate" for the product, indicating readiness for market sales [2] - The approval of Florfenicol will enrich the company’s product line and structure, enhancing its strategic layout in the veterinary medicine sector and improving market competitiveness [3]

Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]

证券代码：002923 证券简称：润都股份 公告编号：2025-021 珠海润都制药股份有限公司 关于公司全资子公司获得兽药产品批准文号批件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，珠海润都制药股份有限公司（以下简称"公司"）全资子公司润都制 药（荆门）有限公司（以下简称"润都荆门公司"）收到国家农业农村部审批签 发的"氟苯尼考"（非无菌原料药）的兽药产品批准文号批件。现将有关情况公 告如下： 一、批件信息 通用名称：氟苯尼考（以下简称"本品"） 企业名称：润都制药（荆门）有限公司 兽药产品批准文号：兽药原字170782108 生产地址：荆门市掇刀区荆门化工循环产业园荆东大道325、327、329号 有效期：2025年04月25日至2030年04月24日 二、产品信息 润都荆门公司已取得本品的《兽药生产许可证》及《兽药GMP证书》，并已将 相关材料上报国家农业农村部，目前已取得本品的批准文号批件，具备上市销售 条件。 三、对公司的影响及风险提示 公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安 全。此次润都荆门公司的氟苯尼 ...

今日焦点中国中车：近期签订合计547.4亿元重大合同 中国中车公告称，公司及下属企业于近期（主要为2024年12月至2025年5月）签订了若干项重大合同， 合计金额约547.4亿元人民币。主要合同包括城市轨道车辆、设备销售及维保合同，动车组销售合同， 动车组高级修合同，风电设备销售合同和储能设备销售合同，机车销售合同以及货车修理合同。上述合 同总金额约占公司中国会计准则下2024年营业收入的22.2%。 阳光诺和：拟购买朗研生命100%股权，股票明日复牌 南方财经5月12日电，阳光诺和(688621.SH)公告称，公司拟通过发行股份及可转换公司债券购买资产并 募集配套资金，购买利虔、朗颐投资等38名朗研生命股东持有的朗研生命100%股权。并向不超过35名 特定投资者发行股份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外 提供药品生产服务，在高端化学药、原料药等领域深耕多年，已经形成了较为成熟的医药生产体系。公 司股票将于5月13日开市起复牌。 沃尔核材：筹划发行H股股票并申请在香港联交所主板上市 沃尔核材公告称，公司拟发行H股股票并申请在香港联交所主板挂牌上市，以推进国际化战略，提升 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"或"本公司"）近日收到国 家药品监督管理局签发的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药品名称：单硝酸异山梨酯片（以下简称"本品"） 剂型：片剂 申请事项：药品注册(境内生产) 规格：20mg 证券代码：002923 证券简称：润都股份 公告编号：2025-020 珠海润都制药股份有限公司 关于单硝酸异山梨酯片获得药品注册证书的公告 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。 二、药品的适应症 本品适用于冠心病的长期治疗；心绞痛的预防；心肌梗死后持续心绞痛的治 疗；与洋地黄和/或利尿剂联合应用，治疗慢性充血性心力衰竭。 三、对公司的影响及风险提示 公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安 全。此次单硝酸异山梨酯片获得国家药监局的《药品注册证书》，进一步丰富了 注册分类：化学药品4类 受理号：CYHS23 ...

Core Viewpoint - The article highlights a trend of decreasing shareholder accounts in several companies, indicating a concentration of shares among fewer investors, with some companies experiencing a significant decline over multiple periods [1][2]. Group 1: Shareholder Account Trends - A total of 101 companies reported their latest shareholder account numbers as of May 10, with 14 companies showing a continuous decline for more than three periods, and some experiencing a drop for up to seven periods [1]. - Notable companies with prolonged declines include Kangxin New Materials, which has 44,113 shareholders, down 26.72% over seven periods, and Dingxin Communications, with 30,474 shareholders, down 21.81% over the same duration [1][2]. - Other companies with significant declines in shareholder accounts include Guotou Intelligent and Changcheng Securities, among others [1]. Group 2: Market Performance - Among the companies with decreasing shareholder accounts, only one has seen its stock price rise, while 13 have experienced declines, with HaiXiang Pharmaceutical showing a notable increase of 1.76% [1]. - In terms of relative performance against the Shanghai Composite Index, only one company outperformed the index, with HaiXiang Pharmaceutical achieving a relative return of 2.93% [1][2]. Group 3: Industry Distribution - The industries with the highest concentration of companies experiencing declining shareholder accounts include machinery equipment, pharmaceuticals, and communications, with three, two, and two companies respectively [2]. - The distribution of these companies shows that eight are listed on the main board and six on the ChiNext board [2]. Group 4: Detailed Company Data - A table lists companies with their latest shareholder accounts, percentage changes, consecutive decline periods, and stock performance, highlighting significant declines for companies like Naipu Mining (-5.40%), Rundu Co., Ltd. (-4.85%), and Aotexun (-1.90%) [2][3]. - Kangxin New Materials and Dingxin Communications are among those with the longest consecutive declines, with respective declines of 0.34% and 0.40% in the latest period [3].